HeMemics Biotechnologies was selected to present its dried biologic stabilization technology platform at Early Stage East (ESE) in Wilmington, DE. ESE is the venture capital showcase for promising companies. ESE is a bridge that serves as a gathering place for entrepreneurs and funding organizations.

HeMemics Biotechnologies will use its proprietary cell drying technology to stabilize RNL BioStar proprietary stem cells for long term storage in dried format. Stem cells have very limited shelf life at 4o Celsius and room temperature and when stored in liquid format. Hence, the current state of technology requires the cells to be stored in frozen format. When use, the cells must be thawed and cultured. At the very least, this process is time consuming; furthermore, each round of freezing and culturing will diminish cells biological functions and their pluripotencies. RNL BioStar Inc. is a Korean based stem cell therapy company that have a proprietary stem cell line to be used for various human therapeutic applications.

HeMemics Biotech announced it has received an investment from The Maryland Technology Development Corporation (TEDCO) Maryland Technology Transfer Fund (MTTF) to develop and commercialize its biologic and cellular stabilization technology.

HeMemics Biotechnologies Inc, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) on cells and biologics dry stabilization program with the University of Maryland (UM) at Baltimore, MD. This research agreement will allow HeMemics to work closely with UM to extend the proof of concept and build a working model for the Company’s dried cell stabilization platform.

HeMemics and LifeStream Animal Blood Bank are initiating a clinical trial to establish safety profile of infusible, dehydrated canine plasma in dogs. This trial is designed to evaluate the safety and tolerability of dehydrated canine plasma in healthy dogs. HeMemics and University of Maryland School of Medicine will produce the dehydrated plasma samples; LifeStream Animal Blood Bank, through the Canadian Ministry of Agriculture, will conduct the clinical trial. HeMemics dehydrated plasma platform is an integrated therapeutic blood stabilization program designed to address several issues plaguing animal blood banks such as outdating, safety, storage and short shelf-life. Dehydrated blood products with extended shelf-life are easy to transport and can be stored at room temperature and will make these life saving blood components more readily available for companion animals. This program is being funded by the Maryland Industrial Partnerships Program, HeMemics and LifeStream.

HeMemics Biotech announced it has received a Phase I Maryland Industrial Partnership (MIPS) Award to develop stabilized blood products for veterinary applications using the company’s proprietary cell drying platform. The Company is collaborating with Dr. Denise Harmening, PhD, MT (ASCP), who is a professor in the Department of Medical and Research Technology, University of Maryland, School of Medicine.
Maryland Industrial Partnerships promotes the development and commercialization of advanced technology through university/industry partnerships. MIPS provides funding to help Maryland companies pay for university research.

Mr. Duc Duong, the president of MDTC indicated that the board had approved HeMemics application to establish its R&D facility in the state of MD Montgomery County.

Dr. Steve Bruttig presented to MTDC council an overview of HeMemics goals and missions. The talk described HeMemics technology, its products and projected job growth that the company may bring to the MD Montgomery County. The presentation was attended by MTDC board of directors, county officials as well as investors. MTDC is an incubator of technology companies funded by MD Montgomery County’s business development.

HeMemics IP is a patent pending process which will serve as a foundation for a series of related patents to be filed in the coming months. This cell preservation technique will expand the shelf-life of nucleated and anucleated cells making them readily available for therapeutics and diagnostics applications. Aside from addressing the long term storage issue, HeMemics technology will allow cells to recover functions far more superior than current storage techniques (ie liquid nitrogen, freezers etc) which have been shown to damage cell membranes and associated receptors.